Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.47 |
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190089 | 0.83 | ALDH1A1 (0.41) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL13764542 | 0.83 | ALDH1A1 (0.40) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL4167066 | 0.80 | ADRA2A (0.40) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL18080714 | 0.78 | PRKCZ (0.42) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL1041240 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL1497728 | 0.76 | ADORA1 (0.54) | HPGDMAPK1PRKCZMEN1KMT2A | |
| SCHEMBL9951934 | 0.75 | POLB (0.40) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL132713 | 0.75 | ALDH1A1 (0.52) | ALDH1A1MAPTHSD17B10TSHRGAA | |
| SCHEMBL8566481 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HPGDGAA | |
| SCHEMBL162443 | 0.75 | ALDH1A1 (0.63) | ALDH1A1MAPTHSD17B10HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8269060-A | — | — | None | — | — | JP | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4214213-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-03-24 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-1436266-A2 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | disclosed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2003024926-A2 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-6114338-A | ENZYME INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| US-6001830-A | INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE, OR ADDITIONALLY OF THROMBOXANE A.SUB.2 SYNTHETASE; TRIAZOLOPYRIDAZINE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5869486-A | EXHIBIT INHIBITORY ACTIVITY ON CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE; ADMINISTERING TO TREAT CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-02-09 | — | — | US | disclosed |
| JP-H08269060-A | HETEROCYCLIC COMPOUND, ITS PRODUCTION AND PHARMACEUTICAL CONTAINING THE COMPOUND | ONO PHARMACEUT CO LTD | 1996-10-15 | — | — | JP | disclosed |
| EP-0728759-A1 | Heterocyclic compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-4180503-A | FOR DYEING POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | ALDH1A1 4529/4885MAPT 51/4885HSD17B10 3960/4885 |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | ALDH1A1 2921/4885MAPT 1795/4885HSD17B10 2827/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | ALDH1A1 2921/4885MAPT 1795/4885HSD17B10 2827/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | ALDH1A1 4529/4885MAPT 51/4885HSD17B10 3960/4885 |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | ALDH1A1 4407/4885MAPT 3539/4885HSD17B10 1873/4885 |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | ALDH1A1 4529/4885MAPT 51/4885HSD17B10 3960/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | ALDH1A1 2921/4885MAPT 1795/4885HSD17B10 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.